You are leaving and being redirected to www.sanofi.us, our parent company, where all product inquiries are handled.

1-877-4MOZOBIL
(1-877-466-9624)

Stem Cell Mobilization

In the past, a bone marrow harvest (a surgical procedure) was the only way to collect stem cells for a transplant. Today it is now possible to collect stem cells from the peripheral blood (from the bloodstream), a process that is easier on you and generally preferred.

If you donate your own stem cells for use in transplant, it is referred to as an autologous stem cell transplant. In order to undergo an autologous transplant, you must have enough stem cells collected to proceed to transplant.

Mobilization

Stem cell mobilization is a process whereby stem cells are stimulated out of the bone marrow space (e.g., the hip bones and the chest bone) into the bloodstream, so they are available for collection for future reinfusion. The cells are then preserved, frozen and stored until the time of transplant.

Some preferred characteristics of a mobilization regimen include:

Mobilizing enough stem cells for transplant
Minimizing the number of days you are on the apheresis (cell separator) machine
Collecting stem cells that allow quick and long lasting (often termed “durable”) recovery of red blood cells, white blood cells and platelets when they are reinfused into your body

Mobilization Options

In addition to Mozobil, other mobilization strategies include growth factor alone or chemotherapy followed by growth factor.

Questions to Ask Your Doctor

Prepare for your next appointment with our list of questions to ask your doctor.

Indication

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Important Safety Information

Mozobil is not intended for HSCT mobilization and collection in patients with leukemia.
Mozobil in combination with G-CSF increases circulating WBCs. Your WBC counts will be monitored.
Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil caused harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reaction (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).